Orgenesis Enters Material Definitive Agreement on Jan 18
Ticker: ORGS · Form: 8-K · Filed: Jan 24, 2024 · CIK: 1460602
| Field | Detail |
|---|---|
| Company | Orgenesis INC. (ORGS) |
| Form Type | 8-K |
| Filed Date | Jan 24, 2024 |
| Risk Level | medium |
| Pages | 3 |
| Reading Time | 4 min |
| Key Dollar Amounts | $40 million, $40 m, $300,000 |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: material-agreement, corporate-event, biotech
TL;DR
**ORGS just signed a big deal, details to follow, could be a game-changer.**
AI Summary
Orgenesis Inc. (ORGS) filed an 8-K on January 24, 2024, reporting an "Entry into a Material Definitive Agreement" that occurred on January 18, 2024. This indicates the company has entered into a significant contract or partnership that could impact its future operations and financial performance. For investors, this matters because material agreements often signal new business opportunities, strategic shifts, or potential revenue streams, which could influence the stock's valuation.
Why It Matters
This filing signals a potentially significant business development for Orgenesis, as a 'material definitive agreement' typically involves substantial commitments or opportunities that could affect the company's financial health and strategic direction.
Risk Assessment
Risk Level: medium — The risk is medium because while a material agreement is reported, the specific details and financial implications are not yet disclosed, making its impact uncertain.
Analyst Insight
A smart investor would monitor Orgenesis Inc. for follow-up announcements or filings that provide specific details about this 'Material Definitive Agreement' to assess its potential impact on the company's financials and future prospects before making any investment decisions.
Key Players & Entities
- Orgenesis Inc. (company) — the registrant filing the 8-K
- January 18, 2024 (date) — date of the earliest event reported (entry into agreement)
- January 24, 2024 (date) — date the 8-K was filed
- 001-38416 (other) — Commission File Number for Orgenesis Inc.
- ORGS (other) — Trading Symbol for Orgenesis Inc. on The Nasdaq Capital Market
Forward-Looking Statements
- Orgenesis Inc. will release further details about the Material Definitive Agreement in a subsequent filing or press release. (Orgenesis Inc.) — high confidence, target: Q1 2024
- The agreement will involve a partnership or collaboration in the pharmaceutical preparations sector. (Orgenesis Inc.) — medium confidence, target: Q2 2024
FAQ
What is the specific nature of the 'Material Definitive Agreement' Orgenesis Inc. entered into?
The filing states that Orgenesis Inc. entered into a 'Material Definitive Agreement' on January 18, 2024, but it does not provide specific details about the nature of this agreement, such as the parties involved, the terms, or the financial implications.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 18, 2024, which is the date Orgenesis Inc. entered into the Material Definitive Agreement.
What is the trading symbol and exchange for Orgenesis Inc.?
Orgenesis Inc.'s common stock trades under the symbol ORGS on The Nasdaq Capital Market.
What is the business address of Orgenesis Inc. as stated in the filing?
The business address of Orgenesis Inc. is 20271 Goldenrod Lane, Germantown, MD 20876.
Why did Orgenesis Inc. file this 8-K?
Orgenesis Inc. filed this 8-K to report an 'Entry into a Material Definitive Agreement' and to include 'Financial Statements and Exhibits,' as required by SEC regulations for significant corporate events.
Filing Stats: 990 words · 4 min read · ~3 pages · Grade level 12.8 · Accepted 2024-01-24 16:05:30
Key Financial Figures
- $40 million — uy out the remaining royalty stream for $40 million of consideration consisting of cash and
- $40 m — ration for Excluded Assets is more than $40 million, the Company shall pay the Seller
- $300,000 — lated by the Term Sheet, up to a cap of $300,000. The foregoing summary of the Term Sh
Filing Documents
- form8-k.htm (8-K) — 41KB
- ex10-1.htm (EX-10.1) — 33KB
- 0001493152-24-003608.txt ( ) — 249KB
- orgs-20240118.xsd (EX-101.SCH) — 3KB
- orgs-20240118_lab.xml (EX-101.LAB) — 33KB
- orgs-20240118_pre.xml (EX-101.PRE) — 22KB
- form8-k_htm.xml (XML) — 3KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. ORGENESIS INC. Date: January 24, 2024 By: /s/ Victor Miller Victor Miller Chief Financial Officer, Treasurer and Secretary